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21% in the second, 53% in the third, and 94% in the fourth line. The most common 
treatment algorithm (18%) was FOLFOX, FOLFIRI and supportive care in the ﬁ rst-, 
second-, and third-lines, respectively. Mean regimen costs per patient were estimated 
from a public payer perspective. The most expensive ﬁ rst, second, third and fourth-line 
regimens were FOLFOX 4 (c14,200), FOLFIRI + bevacizumab (c7912c), cetuximab 
+ irinotecan (c7237) and capecitabine (c2609), respectively. CONCLUSIONS: The 
most common regimen in the ﬁ rst line was also the most expensive one. New chemo-
therapeutic agents are associated with improvements in survival time but also with 
substantial costs. Factors inﬂ uencing the selection of chemotherapy included: previous 
therapies, course of the disease, the patient’s performance status, adverse events after 
previous chemotherapies, and concomitant diseases. However, open-ended coverage 
policies for new chemotherapeutic agents may prove difﬁ cult to sustain as costs 
continue to rise.
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OBJECTIVES: Breast cancer (BC) is the second neoplasm which disseminates brain 
metastases (BM). We estimated the incidence of patients with BCBM, those overex-
pressing HER2 (HER2+), and the costs related to their management using the new 
chaining system of the French hospital information program (PMSI). This was to 
identify predictors of costs. METHODS: A retrospective analysis using the PMSI 
database (2006–2008) was conducted to estimate the number of public and private 
stays related to the diagnosis of BCBM. Stays were extracted and chained to patients’ 
identiﬁ cation number to calculate the number of patients concerned by BCBM. The 
administration of trastuzumab was used as a surrogate for the HER2 status. Costs 
were estimated from the health insurance perspective including health-related group 
tariff, supplements for intensive care, number and length of stays, and expensive-drugs 
status. Spearman’s rank correlation coefﬁ cient and nonparametric test (Kruskal–
Wallis) were used for univariate analyses. RESULTS: In 2008, 3610 women were 
hospitalized for BCBM (vs. 3273 and 3523 in 2006 and 2007, respectively) of whom 
average age was 56.1 years (SD: 13.3). Patients had an average of 4.8 hospitalizations 
(SD: 6.4) mostly for palliative care (42%), chemotherapy (39%), and radiotherapy 
(14%). Twenty-one percent of patients suffered from BM only and 79% had multiple 
metastases; 16% were identiﬁ ed as HER2+. Annual mean cost of care was c8049 per 
patient with BCBM compared with c19,412 speciﬁ cally for HER2+ patients (respec-
tively, 11% and 59% were dedicated to expensive drugs). Age (P < 0.001), patients 
with newly diagnosed BCBM (P < 0.001), and the number of metastases (P < 0.001) 
were associated with the cost of BCBM. CONCLUSIONS: Incidence of BCBM seemed 
to increase during 2006–2008. BCBM management appeared resource-consuming 
especially for HER2+ patients. The development of chaining system in PMSI database 
is an opportunity to estimate economic data accurately as well as to generate epide-
miological data from an exhaustive database.
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OBJECTIVES: Chemotherapy is a major factor contributing to the economic burden 
associated with breast cancer in the elderly. However, there are no clear recommenda-
tions for adjuvant chemotherapy use in elderly women aged 70 and above due to lack 
of efﬁ cacy data in that age group. The study objective was to examine the clinical and 
economic outcomes associated with adjuvant chemotherapy in elderly patients aged 
65 and above with early stage operable breast cancer. METHODS: We studied a 
cohort of 23,110 node positive and 31,572 node negative women aged 65 and over 
diagnosed with incident American Joint Committee on Cancer (AJCC) stage I, II, or 
IIIa breast cancer between January 1, 1991 and December 31, 2002 using SEER-
Medicare data. Total treatment and chemotherapy costs were estimated from the 
Medicare payments using the phase of care approach. Cox proportional hazard ratio 
of mortality was used to determine the effectiveness of adjuvant chemotherapy after 
adjusting for selected patient and tumor characteristics. a propensity score analysis 
was also employed to minimize the bias associated with the receipt of adjuvant che-
motherapy. RESULTS: The difference in the total unadjusted costs for patients who 
received chemotherapy in contrast with patients not receiving any chemotherapy was 
$16,795 in node positive patients and $11,882 in node negative patients. Regression 
adjusted cost estimates for all node positive patients receiving chemotherapy was 
approximately $6500 and was signiﬁ cantly higher (P < 0.05) than for patients not 
receiving chemotherapy. Mortality was signiﬁ cantly reduced in node positive women 
aged 65–69 who received adjuvant chemotherapy compared to those who did not 
receive chemotherapy (HR, 0.66; CI, 0.58–0.74) and in patients aged 70–74 (HR,0.66; 
CI, 0.59–0.74), after adjustment for factors that may affect survival. CONCLUSIONS: 
Decision makers can use cost and effectiveness estimates from this study to assess rela-
tive value of chemotherapy in different age groups.
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OBJECTIVES: To evaluate the cost of biweekly oxaliplatin plus oral capecitabine 
(OXXEL) versus oxaliplatin combined with leucovorin-modulated 5-ﬂ uorouracil 
(5-FU) given as i.v. bolus every 2 weeks (OXAFAFU) in patients with metastatic 
colorectal cancer (MCRC) in Italy. METHODS: We conducted a multicenter, retro-
spective longitudinal treatment-cost analysis. Direct medical costs attributable to 
MCRC were quantiﬁ ed using 2008 prices and tariffs. The analysis was applied to a 
time horizon of 6 months. The study was conducted from the perspective of the 
National Healthcare Service (NHS). RESULTS: A total of 322 patients (59.9% males; 
mean age 65.2 ± 9.4 years) were analyzed. Mean total cost per patient over follow-up 
period was estimated at c5242.18 ± 2542.06 and c6732.80 ± 3423.72 in the 
Capecitabine and 5-FU arms respectively (P < 0.0001). CONCLUSIONS: The study 
estimated that oral capecitabine administration would produce a saving of c1490.62 
to the NHS. The differences in cost between the two arms are determined by the 
administration route (i.v. vs. oral administration). Therefore, the important economic 
and practical advantage of capecitabine oral home-based therapy is the reduced 
number of hospital visit and the relative costs. Avoiding the hospital access fees 
reduces the impact of higher acquisition cost of capecitabine. Moreover, capecitabine 
in comparison to the 5-FU regimen was associated with lower complication. There-
fore, oral capecitabine may represent a valid alternative in the management of meta-
static colorectal cancer.
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OBJECTIVES: To describe chemotherapy regimens used in the ﬁ rst-, second-, and 
third-line treatment of patients with metastatic colorectal cancer and to estimate costs 
of regimens, supportive care, and medical procedures in Slovakia (part of a multina-
tional study in central Europe). METHODS: In this opinion-based study, data were 
collected by online questionnaire. All information concerning treatment of colorectal 
cancer was based on expert opinion at three oncology centers in Slovakia. Oncologists 
had access to medical records of approximately 1600 patients treated in year 2008. 
RESULTS: The most commonly used ﬁ rst-line regimen (27% of patients) was IFL 
(irinotecan, 5-FU, leucovorin) + bevacizumab. The most commonly prescribed second-
line regimen (27%) was cetuximab + irinotecan and capecitabine was the most 
common third-line regimen (15%). None of patients received supportive care in the 
ﬁ rst line. The percentages of patients receiving supportive care in the second and third 
lines were 27% and 45%, respectively. The most common treatment strategy (8%) 
was ﬁ rst-line capecitabine and supportive care in the second line. Mean regimen costs 
per patient were estimated from a public payer perspective. The most expensive ﬁ rst-
line regimen was IFL + bevacizumab (c36,369). In the second and third lines, modiﬁ ed 
FOLFOX 4 (oxaliplatin, 5-FU, leucovorin) was the most expensive regimen at c31,318 
and c31,572, respectively. CONCLUSIONS: More than 50% of patients received an 
active treatment until the second line. The most common regimen in the ﬁ rst line was 
also the most expensive one. New chemotherapeutic agents are associated with 
improvements in survival time but also with substantial costs. Factors inﬂ uencing the 
selection of chemotherapy included: previous therapies, course of the disease, the 
patient’s performance status, adverse events after previous chemotherapies and con-
comitant diseases. However, open-ended coverage policies for new chemotherapeutic 
agents may prove difﬁ cult to sustain as costs continue to rise.
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OBJECTIVES: To describe chemotherapy regimens used and to estimate costs of 
chemotherapy regimens, supportive care, and medical procedures in the ﬁ rst-, second-, 
third-, and fourth-line treatment of patients with metastatic colorectal cancer in Serbia 
(part of a multinational study in central Europe). METHODS: An online questionnaire 
was used to collect necessary information in this opinion-based study. All information 
concerning treatment of colorectal cancer was based on experts opinion from four 
oncology centers in Serbia. Oncologists had access to medical records of approxi-
mately 1760 patients treated in year 2008. RESULTS: The leading ﬁ rst-line regimen 
(38% of patients) was Mayo (Folinic acid, 5-FU). The most commonly prescribed 
second-line regimen (46%%) was FOLFOX 4. Modiﬁ ed FOLFIRI (irinotecan, folinic 
acid, 5-FU) was the most popular regimen in the third line (35%), while FOLFIRI/
cetuximab (35%) was the most commonly used fourth-line regimen. The percentage 
of patients receiving supportive care was 7%, 5%, 10%, and 56% in the ﬁ rst, second, 
third, and fourth lines, respectively. The most common treatment path (8%) was 
FOLFOX 4 B in the ﬁ rst line, FOLFIRI B in the second, and Mitomicin mono in the 
third. Mean regimen costs per patient were estimated from a public payer perspective. 
The most expensive regimen in the ﬁ rst line was bevacizumab + capecitabine + oxali-
